AMENDMENTS TO THE CLAIMS

Please amend claims 1, 4, 9-10, 13-21, and 23-24 as indicated below.

Please cancel claim 11 without prejudice.

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently Amended) An isolated compound ~~having~~ of the structure (I):



(I)

wherein:

R_1 is a substituted alkyl;

R_2 is methyl;

R_3 is hydroxy;

Each R_4 is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, or substituted cycloalkyl;

E_1, E_3, and E_4 are–O;

E_2 is $-NR_5$, wherein R_5 is –H or C_1-C_6 alkyl; and

X is 0 to 8.

2. (Previously Presented) The compound of Claim 1, wherein E_2 is -NH.

3. (Canceled).

4. (Currently Amended) The compound of Claim 1, wherein R_1 is a substituted alkyl substituted with one or more ~~substitutions~~ substituents selected from the group consisting of halogen, cyano, oxyacyl, amino, amido, -C(O)H, acyl, carboxyl, and sulfonamide.

5. (Original) The compound of Claim 4, wherein the substituted alkyl is a halogenated alkyl.

6. (Original) The compound of Claim 5, wherein the halogenated alkyl is a chlorinated alkyl.

7. (Previously Presented) A pharmaceutical composition comprising at least one compound of Claim 1 in a pharmaceutically acceptable carrier thereof.

8. (Canceled).

9. (Currently Amended) The pharmaceutical composition of Claim 7, further comprising at least one ~~additional~~ anti-neoplastic agent in combination with the at least one compound of claim 1.

10. (Currently Amended) A method of treating a human refractile ~~mammalian cancer~~ cell proliferative disorder, comprising ~~administering to a subject in need thereof~~ contacting human refractile cancer cells with a therapeutically effective amount of a compound ~~having~~ of the structure (I):



(I)

wherein:

R_1 to R_3 are each independently -H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, -C(O)H, acyl, oxyacyl, carbamate, sulfonamide, or sulfuryl;

Each R_4 is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, or substituted cycloalkyl;

E_1 to E_4 are each independently -O,- NR_5, or -S, wherein R_5 is -H or C_1-C_6 alkyl; and

X is 0 to 8.

11. (Canceled).

12. (Currently Amended) The method of Claim 10, wherein the compound ~~has~~ is of the structure ~~of formula~~ (V):



(V).

13. (Currently Amended) The method of Claim 10, wherein the human refractile ~~cancer~~ cell proliferative disorder is selected from the group consisting of ~~a~~ mammary cancer ~~cell~~, ~~a~~ small-cell lung cancer ~~cell~~, ~~a~~ non-small-cell lung cancer ~~cell~~, ~~a~~ colorectal cancer ~~cell~~, ~~a~~ leukemia ~~cancer cell~~, ~~a~~ melanoma ~~cancer cell~~, ~~a~~ pancreatic adenocarcinoma ~~cancer cell~~, ~~a~~ central nervous system (CNS) cancer ~~cell~~, ~~an~~ ovarian cancer ~~cell~~, ~~a~~ prostate cancer ~~cell~~, ~~a~~ sarcoma ~~cell~~ of ~~a~~ soft tissue ~~cancer~~, ~~a~~ sarcoma ~~cell~~ of ~~a~~ bone, ~~a~~ head cancer ~~cell~~, ~~a~~ neck cancer ~~cell~~, ~~a~~ gastric cancer ~~cell~~, ~~a~~ thyroid cancer ~~cell~~, ~~a~~ stomach cancer ~~cell~~, ~~a~~ myeloma ~~cancer cell~~, ~~a~~ bladder cancer ~~cell~~, ~~a~~ renal cancer ~~cell~~, ~~a~~ neuroendocrine cancer ~~cell~~, a non-Hodgkin's ~~cancer~~ disease, ~~cell~~ and ~~a~~ Hodgkin's disease ~~cancer cell~~.

14. (Currently Amended) The method of Claim 13, wherein the human refractile ~~cancer~~ cell proliferative disorder is a sarcoma ~~cell~~ of a soft tissue or a sarcoma ~~cell~~ of a bone.

15. (Currently Amended) The method of Claim 13, wherein the human refractile ~~cancer~~ cell proliferative disorder is a leukemia ~~cancer cell~~.

16. (Currently Amended) The method of Claim 13, wherein the human refractile ~~cancer~~ cell proliferative disorder is a myeloma ~~cancer cell~~.

17. (Currently Amended) The method of Claim 13, wherein the human refractile ~~cancer~~ cell proliferative disorder is ~~an~~ ovarian cancer ~~cell~~.

18. (Currently Amended) The method of Claim 13, wherein the human refractile ~~cancer~~ cell proliferative disorder is ~~a~~ prostate ~~cancer cell~~.

19. (Currently Amended) The method of Claim 13, wherein the human refractile ~~cancer~~ cell proliferative disorder is ~~a~~ non-Hodgkin's disease ~~cancer cell~~.

20. (Currently Amended) The method of Claim 13, wherein the human refractile ~~cancer~~ cell proliferative disorder is a pancreatic adenocarcinoma ~~cancer cell~~.

21. (Currently Amended) The method of Claim 10, wherein: R_1 is a substituted alkyl; R_2 is methyl; R_3 is hydroxy; each R_4 is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, or substituted cycloalkyl; E_1, E_4 and E_3 are -O; E_2 is $-NR_5$, wherein R_5 is –H or C_1-C_6 alkyl; and X is 0 to 8.

22. (Previously Presented) The method of Claim 21, wherein R_1 is a halogenated alkyl.

23. (Currently Amended) The method of Claim 10, further comprising administering at least one ~~additional~~ anti-neoplastic agent in combination with at least one compound of the structure (I).

24. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of a compound ~~having~~ of the structure:



wherein the pharmaceutical composition is in a solid form.

25. (Previously Presented) The compound of Claim 1, wherein the structure is: